aid: nabla-bio
name: Nabla Bio
description: 'Nabla Bio is a Cambridge, Massachusetts biotechnology company founded
  in 2021 as a Harvard spinout, building generative protein design systems for de novo
  biologics discovery. Its platform is JAM (Joint Atomic Modeling), a multimodal generative
  model trained on large-scale protein sequence and structure data that takes partial
  molecular context — a disease target or an epitope — and computationally designs
  the rest, producing de novo antibodies, VHH-Fc and full-length mAb formats, epitope
  scaffolds, cytokines, receptor traps and multi-domain multispecifics. The company
  pairs the model with an integrated wet lab that feeds mammalian, cellular and in
  vivo measurements back into training, and has published work on de novo design of
  GPCR-targeting antibodies against CXCR4 and CXCR7. Nabla Bio engages exclusively
  through pharmaceutical partnership and molecule licensing — with AstraZeneca, Bristol
  Myers Squibb and Takeda — and does not operate a public developer program, API, SDK
  or self-serve platform.'
url: https://raw.githubusercontent.com/api-evangelist/nabla-bio/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: false
  label: Hosted service · you call their endpoint
  confidence: medium
  source:
  - pricing
  generated: '2026-08-28'
  method: derived
specificationVersion: '0.20'
created: '2026-08-26'
modified: '2026-08-26'
tags:
- Company
- Biotechnology
- Life Sciences
- Drug Discovery
- Protein Design
- Artificial Intelligence
- Machine-Learning
- Antibodies
- Generative Models
- Pharmaceuticals
tags_raw:
- Company
- Biotechnology
- Life Sciences
- Drug Discovery
- Protein Design
- Artificial Intelligence
- Machine Learning
- Antibodies
- Generative Models
- Pharmaceuticals
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/nabla-bio-domain-security.yml
- type: Website
  url: https://www.nabla.bio/
- type: Platform
  url: https://www.nabla.bio/platform
- type: Partner
  url: https://www.nabla.bio/partner
- type: News
  url: https://www.nabla.bio/news
- type: Team
  url: https://www.nabla.bio/team
- type: Careers
  url: https://www.nabla.bio/careers
- type: PrivacyPolicy
  url: https://www.nabla.bio/privacy-policy
- type: Plans
  url: plans/nabla-bio-plans-pricing.yml
- type: RateLimits
  url: rate-limits/nabla-bio-rate-limits.yml
- type: Packages
  url: packages/nabla-bio-packages.yml
- type: LLMsTxt
  url: llms/nabla-bio-llms.txt
x-enrichment:
  date: '2026-08-26'
  status: minimal
  artifacts_added: 6
  pass: local-v1
x-coverage:
  state: none
  reason: no-developer-program
  detail: >-
    Nabla Bio sells generative protein design through pharmaceutical partnership and
    molecule licensing only — its five-page Vercel-hosted marketing site has no docs,
    developer or API route at all, and every spec and .well-known path returns a real
    404 on www.nabla.bio.
  evidence:
  - url: https://www.nabla.bio/openapi.json
    status: 404
  - url: https://www.nabla.bio/docs
    status: 404
  - url: https://www.nabla.bio/.well-known/agent-card.json
    status: 404
  - url: https://www.nabla.bio/partner
    status: 200
  checked: '2026-08-26'